Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jessica T Babic"'
Publikováno v:
Open Forum Infectious Diseases. 9
Background Agents commonly used as oral step-down therapy in Enterobacterales bacteremia include fluoroquinolones and TMP-SMX. The use of these oral agents have been associated with adverse events. Oral β-lactams are not recommended to treat Enterob
Autor:
Anne J Gonzales-Luna, Joshua M. Knight, Rachel S. Britt, Jessica T. Babic, Sarah L. Spitznogle, Selena N. Pham, Patrick M. McDaneld, Joshua A. Hendrickson
Publikováno v:
Journal of Pharmacy Practice. 34:800-813
Purpose To provide a summary of the most prominent peer-reviewed infectious diseases (ID) pharmacotherapy and Human Immunodeficiency Virus (HIV)-related articles published in 2019. Summary Houston Infectious Diseases Network (HIDN) members were asked
Autor:
Jessica T. Babic, Judy O. Ikwuagwu, Margaret Babin, Samuel L. Aitken, Kelly Echevarria, Wai-Ying M. Lam, Katherine K. Perez, Amelia K. Sofjan
Publikováno v:
American Journal of Health-System Pharmacy. 74:238-252
Purpose The most important articles on infectious diseases (ID) pharmacotherapy published in the peer-reviewed literature in 2015, as nominated and selected by panels of pharmacists and others with ID expertise, are summarized. Summary Members of the
Publikováno v:
Diagnostic microbiology and infectious disease. 93(4)
We evaluated 30-day mortality in patients with Pseudomonas aeruginosa bacteremia. There was no significant difference in mortality among patients who received functional aminoglycoside monotherapy versus inappropriate empiric therapy. Among patients
Autor:
Kimberly R. Ledesma, Jessica T. Babic, Vincent H. Tam, Pooja Manchandani, Jian Zhou, Luan D. Truong
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
Despite dose-limiting nephrotoxic potentials, polymyxin B has reemerged as the last line of therapy against multidrug-resistant Gram-negative bacterial infections. However, the handling of polymyxin B by the kidneys is still not thoroughly understood
Autor:
Vincent H. Tam, Thundon Ngamprasertchai, Adhiratha Boonyasiri, Pooja Manchandani, Yanina Dubrovskaya, Jessica T. Babic, Visanu Thamlikitkul
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
Polymyxin B remains the last-line treatment option for multidrug-resistant Gram-negative bacterial infections. Current U.S. Food and Drug Administration-approved prescribing information recommends that polymyxin B dosing should be adjusted according
Publikováno v:
Open Forum Infectious Diseases
Background The use of rapid diagnostic tests (RDT) in microbiology decreases time to pathogen identification (ID). When coupled with an Antimicrobial Stewardship Program (ASP), time to optimal antibiotics can be significantly reduced. The purpose of